News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

|Articles|May 1, 2005

Eye on Washington

Door opens for return of ephedra, cancer-risk guidelines offered, greater scrutiny of NSAIDs

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

Late preterm hypoglycemia not linked to neurodevelopment at age 6 | Image Credit: © Goffkein - stock.adobe.com

Late preterm hypoglycemia not linked to neurodevelopment at age 6

ByJoshua Fitch, Senior Editor

July 29th 2026

Ensitrelvir now available in US for COVID-19 postexposure prophylaxis | Image Credit: © Production Perig - stock.adobe.com

Ensitrelvir now available in US for COVID-19 postexposure prophylaxis

ByContemporary Pediatrics Staff

July 28th 2026

FDA clears pediatric Patient State Index for Masimo SedLine sedation monitoring

FDA clears pediatric Patient State Index for Masimo SedLine sedation monitoring

ByContemporary Pediatrics Staff

July 28th 2026

Omalizumab outperforms multiallergen oral immunotherapy in multifood allergy trial | Image Credit: © Graphicroyalty - stock.adobe.com.

Omalizumab outperforms multiallergen oral immunotherapy in multifood allergy trial

ByMorgan Ebert, Executive Editor

July 27th 2026

Garadacimab demonstrates positive results in phase 3b trial for pediatric HAE prophylaxis | Image Credit: © Gorodenkoff - stock.adobe.com.

Garadacimab demonstrates positive results in phase 3b trial for pediatric HAE prophylaxis

ByContemporary Pediatrics Staff

July 27th 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

FDA approves centanafadine for ADHD in children, adolescents, and adults

Ensitrelvir now available in US for COVID-19 postexposure prophylaxis

FDA clears pediatric Patient State Index for Masimo SedLine sedation monitoring

FDA approves acetaminophen-naproxen sodium combination tablet for ages 12 and older

Omalizumab outperforms multiallergen oral immunotherapy in multifood allergy trial